Drug intelligence / Profile preview

UT 380

Development stage
Unknown
Lead developer
Laboratoire CCD
Administration
Intrauterine
01

Overview

**UT 380** is a long-acting, non-hormonal *copper-based intrauterine device (IUD)* used for contraception. Its main active ingredient is copper, which is wound around a flexible polyethylene frame. Once inserted into the uterus, the copper ions exert a cytotoxic effect on sperm and egg, inhibiting fertilization and preventing implantation of a fertilized egg. It is effective immediately upon insertion and can be used both as a regular contraceptive method and as emergency contraception if inserted within 5 days (some sources specify up to 7 days) after unprotected intercourse. The device is reversible, suitable for a range of women (nulliparous, primiparous, multiparous), and provides protection for up to 5 years. UT 380 contains barium sulphate for radiopacity and includes a nylon thread for removal[1][4][6].

Brand names
UT 380UT380UT-380Liberte UT 380UT 380 StandardUT380 StandardUT-380 Standard
Other names
UT380UT-380UT 380UT380RUT-380RUT 380R
02

Targets

PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on UT 380.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UT 380.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call